Medical Developments International Limited (MDDVF) Q4 2026 Earnings Call Transcript

Operator

Thank you for standing by, and welcome to the Medical Developments International FY ’26 Full Year Results Call. [Operator Instructions]

I would now like to hand the conference over to Mr. Brent MacGregor, CEO. Please go ahead.

Brent MacGregor
Chief Executive Officer

Thank you very much. Good morning, everyone. Welcome to today’s investor briefing for our FY ’26 full year results. I am Brent MacGregor, I’m the CEO, and I’m joined today by Anita James, our Chief Financial Officer.

So today, I’m going to share with you an overview of our results and the company’s key achievements in the year and take you through our priorities for FY ’27. Anita will speak to the financials in more detail, after which I will give some closing remarks. And then as usual, we’ll have plenty of time for questions at the end of the presentation.

So on that note, why don’t we jump to Slide 4, and I’ll walk you through the key messages we want to convey today. So in short, our strategy to grow Penthrox, it continues to gain momentum. And as evidenced by our results in FY ’26, where we made some great progress.

We delivered a solid financial performance with very strong cash flow generation and earnings in both our Pain Management and Penthrox and in our respiratory segments were materially improved. And in that regard, free cash flow landed at $4.2 million.

So Penthrox in-market demand, it continues to grow, and it continues to grow across all of our jurisdictions. But we achieved some really significant milestones in FY ’26. A significant one in Europe was achieving the approval for the